MedElevator
Войти в исследования Journal of perinatology : official journal of the California Perinatal Association · 2026
Vasopressin for hemodynamic support in neonates: current evidence and clinical applications.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Surak Aimann, Sewidan Mohamed, Kuan Mimi T Y, Kennedy Megan, Kumar Manoj, Ting Joseph Y
Аннотация
OBJECTIVE: To systematically map and synthesize the available evidence on the use of vasopressin for hemodynamic support in neonates.
STUDY DESIGN: We conducted a scoping review to synthesize available data on indications, dosing, clinical effects, and safety.
RESULTS: Twelve studies were included (one randomized trial, eleven observational), encompassing heterogeneous neonatal populations. Vasopressin was primarily used as rescue therapy in refractory shock, including sepsis, persistent pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. Dosing regimens varied widely. Most studies reported improvements in mean arterial blood pressure, with some demonstrating reduced vasoactive support and improved oxygenation. Effects on urine output were variable. Safety reporting was inconsistent; hyponatremia was the most commonly described adverse event, while serious ischemic complications were rarely reported.
CONCLUSION: Vasopressin may improve short-term hemodynamic parameters, but evidence is limited and heterogeneous, with insufficient data to guide optimal use.
STUDY DESIGN: We conducted a scoping review to synthesize available data on indications, dosing, clinical effects, and safety.
RESULTS: Twelve studies were included (one randomized trial, eleven observational), encompassing heterogeneous neonatal populations. Vasopressin was primarily used as rescue therapy in refractory shock, including sepsis, persistent pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. Dosing regimens varied widely. Most studies reported improvements in mean arterial blood pressure, with some demonstrating reduced vasoactive support and improved oxygenation. Effects on urine output were variable. Safety reporting was inconsistent; hyponatremia was the most commonly described adverse event, while serious ischemic complications were rarely reported.
CONCLUSION: Vasopressin may improve short-term hemodynamic parameters, but evidence is limited and heterogeneous, with insufficient data to guide optimal use.